Harvard Bioscience Inc has 7 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| William Snider | 15.97% | 846,000 | SCHEDULE 13D, 2026-03-23 | 2025-12-17 |
| Leviticus Partners LP | 5.2% | 235,000 | SCHEDULE 13G/A, 2026-09-22 | 2026-09-14 |
| BlackRock, Inc. | 2.5% | 1,113,926 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
Purpose of Transaction (Item 4)
William Snider
The information contained above in Item 1 and Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities of the Issuer in connection with the Loan Agreement. Mr. Snider serves a member of the board of directors of the Issuer and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Mr. Snider is a partner of BroadOak Capital Partners and manager of BroadOak Income Fund and BroadOak Fund VI. Subject to the Issuer's Insider Trading Policy and other applicable policies, Mr. Snider may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances, and may receive compensation from the Issuer, in the form of cash, equity or otherwise, in connection with his service as a director of the Issuer. Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, subject to the agreements described herein, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management of the Issuer or the board of directors of the Issuer with respect to the …The first part of Item 4 of the SCHEDULE 13D filed 2026-03-23; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 2.5% | SCHEDULE 13G/A |
| 2025-08-07 | Leviticus Partners LP | 9.2% | SCHEDULE 13G/A |
| 2025-11-03 | Leviticus Partners LP | 7.5% | SCHEDULE 13G/A |
| 2026-02-12 | Leviticus Partners LP | 7.6% | SCHEDULE 13G/A |
| 2026-03-23 | William Snider | 15.97% | SCHEDULE 13D |
| 2026-05-14 | Leviticus Partners LP | 6.5% | SCHEDULE 13G/A |
| 2026-09-22 | Leviticus Partners LP | 5.2% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Harvard Bioscience Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.